INSMED Inc — Director's Dealing 2025

Feb 20, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: INSMED Inc (INSM)
CIK: 0001104506
Period of Report: 2025-02-18

Reporting Person: Lewis William (Director, Chair and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-02-18	Common Stock	M	18750	$22.76	Acquired	352936	Direct
2025-02-18	Common Stock	S	1253	$79.95	Disposed	351683	Direct
2025-02-18	Common Stock	S	16743	$81.08	Disposed	334940	Direct
2025-02-18	Common Stock	S	754	$81.67	Disposed	334186	Direct
2025-02-18	Common Stock	M	6830	$10.85	Acquired	240754	Indirect
2025-02-18	Common Stock	S	456	$80	Disposed	240298	Indirect
2025-02-18	Common Stock	S	6074	$81.07	Disposed	234224	Indirect
2025-02-18	Common Stock	S	300	$81.81	Disposed	233924	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-02-18	Stock Option (right to buy)	$22.76	M	18750	Disposed	2025-05-21	Common Stock (18750)	Direct
2025-02-18	Stock Option (right to buy)	$10.85	M	6830	Disposed	2026-05-19	Common Stock (6830)	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	50500	Indirect

Footnotes

F1: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F2: Since the date of the last ownership report for the Reporting Person, he transferred 92,155 shares of Company common stock, employee stock options to purchase 1,064,717 shares of Company common stock, and restricted stock units covering 27,553 shares of Company common stock to his ex-spouse pursuant to a mutually agreed divorce settlement approved by a court that qualifies as a domestic relations order. A domestic relations order is a court order that dictates how assets should be divided between spouses during a divorce, including securities in the Company. The Reporting Person no longer reports as beneficially owned any securities owned by his ex-spouse.

F3: This is the weighted average sales price representing 1,253 shares sold at prices ranging from $79.50 to $80.35 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

F4: This is the weighted average sales price representing 16,743 shares sold at prices ranging from $80.50 to $81.43 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

F5: This is the weighted average sales price representing 754 shares sold at prices ranging from $81.56 to $81.78 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

F6: This is the weighted average sales price representing 456 shares sold at prices ranging from $79.50 to $80.34 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

F7: This is the weighted average sales price representing 6,074 shares sold at prices ranging from $80.51 to $81.42 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

F8: This is the weighted average sales price representing 300 shares sold at prices ranging from $81.69 to $82.01 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

F9: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable.